CA
ALGS icon

Cliff Asness’s Aligos Therapeutics ALGS Stock Holding History

Cliff Asness’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,922
Closed -$58K – 2179
2022
Q2 		$58K Buy
+1,922
New +$65.3K ﹤0.01% 2125

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cliff Asness's ALGS Position: Q3 2022 in Review

Cliff Asness sold out of Aligos Therapeutics (ALGS) in Q3 2022, closing a stake of 1,922 shares — an estimated $58K sold.

Cliff Asness first reported a position in ALGS in Q2 2022 and held it in 1 quarter. The position peaked at $58K in Q2 2022. 52 funds tracked by Wall St. Rank hold ALGS as of Q3 2022.

  • Cliff Asness reported no remaining Aligos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cliff Asness sold 1,922 Aligos Therapeutics shares in Q3 2022, an estimated $58K.
  • Cliff Asness first reported a position in Aligos Therapeutics in Q2 2022 and held it in 1 quarter.
  • Cliff Asness's Aligos Therapeutics position peaked at $58K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.